Vogenx, Inc. (VOGX) Stock Forecast Oct. 30, 2026
Analysis updated on Oct. 30, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Vogenx, Inc. (VOGX) stock forecast summary
This forecast was produced 4 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Vogenx, Inc. is a small-cap company with a market capitalization of $296M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Current Ratio of 0.44x is the lowest of the 58 peers that report one.
A per-ticker accuracy statistic for VOGX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
VOGX price chart and AI forecast
How VOGX ranks among 4891 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Vogenx, Inc. (VOGX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | VOGX | Rank |
|---|---|---|
| Market Cap | $296M | 60/60 |
Financial Health
| Metric | VOGX | Rank |
|---|---|---|
| Current Ratio | 0.44x | 58/58 |
| Working Capital | -$2M | 53/58 |
Dividend & Shareholder Information
| Metric | VOGX | Rank |
|---|---|---|
| Shares Outstanding | 15M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1M | |
| Cash & Short-term Investments | $190K | |
| Total Liabilities | $3M | |
| Short-term Debt | $2M |
VOGX quarterly financials and insider trading
Vogenx, Inc. (VOGX) industry peers
Companies classified under the same SEC industry code as Vogenx, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| VOGX Vogenx, Inc. | $296M | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $665.19B | |
| ABBV Abbvie Inc. | $521.00B | |
| MRK Merck & Co., Inc. | $370.96B | |
| NVS Novartis Ag | $303.89B | |
| AZN Astrazeneca Plc | $285.01B | |
| ABT Abbott Laboratories | $200.85B | |
| NVO Novo Nordisk A S | $187.45B | |
| PFE Pfizer Inc | $170.99B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $136.87B | |
| BMY Bristol Myers Squibb Co | $131.21B | |
| SNY Sanofi | $106.33B | |
| GSK Gsk Plc | $103.19B | |
| REGN Regeneron Pharmaceuticals, Inc. | $100.21B | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | |
| TEVA Teva Pharmaceutical Industries Ltd | $48.84B | |
| ONC Beone Medicines Ltd. | $40.36B | |
| GMAB Genmab A/S | $35.46B | |
| ZTS Zoetis Inc. | $34.29B | |
| RPRX Royalty Pharma Plc | $28.77B | |
| ROIV Roivant Sciences Ltd. | $26.03B | |
| UTHR United Therapeutics Corp | $25.79B | |
| INSM Insmed Inc | $24.13B | |
| VTRS Viatris Inc | $21.73B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.57B | |
| ASND Ascendis Pharma A/S | $16.93B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.23B | |
| BBIO Bridgebio Pharma, Inc. | $14.42B | |
| SMMT Summit Therapeutics Inc. | $12.60B | |
| ELAN Elanco Animal Health Inc | $12.28B | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | |
| BMRN Biomarin Pharmaceutical Inc | $11.06B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.25B | |
| TGTX Tg Therapeutics, Inc. | $9.22B | |
| PTGX Protagonist Therapeutics, Inc | $9.07B | |
| CORT Corcept Therapeutics Inc | $8.86B | |
| CYTK Cytokinetics Inc | $8.84B | |
| SYRE Spyre Therapeutics, Inc. | $8.75B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.71B | |
| PRAX Praxis Precision Medicines, Inc. | $7.83B | |
| ALKS Alkermes Plc. | $7.70B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.55B | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | |
| AXSM Axsome Therapeutics, Inc. | $7.18B | |
| ABVX Abivax S.A. | $6.97B | |
| ORKA Oruka Therapeutics, Inc. | $6.59B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.37B | |
| LGND Ligand Pharmaceuticals Inc | $6.32B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.30B | |
| BLTE Belite Bio, Inc | $5.99B | |
| PTCT Ptc Therapeutics, Inc. | $5.69B | |
| MANE Veradermics, Inc | $5.58B | |
| COGT Cogent Biosciences, Inc. | $5.46B | |
| ERAS Erasca, Inc. | $5.21B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.80B | |
| TVTX Travere Therapeutics, Inc. | $4.42B | |
| ARQT Arcutis Biotherapeutics, Inc. | $4.28B | |
| LQDA Liquidia Corp | $4.24B |
Where VOGX sits on the market map
Vogenx, Inc. (VOGX) stock news
Loading...
Vogenx, Inc. (VOGX) stock forecast FAQ
What is the Vogenx, Inc. (VOGX) stock forecast?
This forecast was produced 4 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Vogenx, Inc. stock predictions?
A per-ticker accuracy statistic for VOGX is published only once its sample size is known. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Vogenx, Inc. forecasts updated?
Vogenx, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 30, 2026.
Which companies are Vogenx, Inc.'s industry peers?
60 issuers in our coverage, VOGX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.